Latest News
These are CLL Ireland’s latest news posts from Facebook – but make sure to visit our CLL Ireland Facebook page for older posts.
Our own Jan & Michael Rynne had the honour of meeting #CLL expert Professor John Seymour Associate Director of Clinical Research from Australia's Peter MacCallum Cancer Centre, here in Dublin this morning. Our #bloodcancer community owe clinicians & researchers like him a debt of gratitude.
#CLL expert Dr. Jeff Sharman explains what patients with a 17p deletion should be aware of when making treatment and explains how genetic mutations can influence frontline therapy | via Patient Power - a Cancer Community ow.ly/XiR030nISzQ
Is Chemo Safe for CLL Patients With a 17p Deletion?
patientpower.info
What role does the 17p deletion play in determining the beginning of treatment? Tune in to hear CLL expert Dr. Jeff Sharman explain.To all our followers please share to help ensure the patient voice of those in our #bloodcancer community with an Acute #Leukemia #leukaemia is also heard. #AML #ALL
..
#patientsinvolved
#patientsfirst
ow.ly/cMeN30nHW13
Acute Leukemia Advocates Network
Have you been diagnosed with acute #leukemia? We’re running a global survey about Quality of Life whilst living with acute leukaemia. We would like to ask you about your experiences of living with the disease – throughout your treatment journey and beyond.A diagnosis can have a huge emotional impact and long periods spent alone in hospital can be isolating for patients. The survey results will be used to help understand and quantify the key issues, experiences, and unmet needs for patients throughout the journey with acute leukaemia.
Share your experience and help drive improvements for future patients #ALQOL #AML #ALL
www.myonlinesurvey.co.uk/ALAN/
"Rapid and complete response to idelalisib in a case of Richter Syndrome (RS)"
Interesting report indicates "idelalisib is highly effective in RS and provides an attractive option in this aggressive disease...& a treatment option... for elderly patients with RS" | via Dove Medical Press
Do you have 2 minutes to help us by completing our short patient experience survey?
Your results will help us provide information of relevance to our community to help patients save time and energy on their patient journey.
www.questionpro.com/t/AO5PfZdjYN
While it will be a while before the outcome of this powerful new therapy is known, the treatment has shown very promising results in #clinicaltrials
NHS England has also agreed to fund another CAR-T therapy for adults with lymphoma | via BBC News (UK)
www.bbc.co.uk/news/health-47058069
Pioneering cancer therapy for first child
bbc.com
An 11-year-old-boy with leukaemia is the first patient to get a personalised therapy paid for by the NHS."How Does CLL Affect Sinuses and the Skin?" #CLL experts address this and other questions about monitoring patients immunity, infections, allergies and skin protection| via Patient Power - a Cancer Community YouTube youtu.be/KxT4cV1ls7IAt a recent town meeting an audience member asked, “do people with CLL have more sinus issues?” How critical is skin care for those living with chronic lymph...
"Hearing the news that you have cancer, and especially HOW you receive it, has a very real impact on both your mental and physical health... If your oncologist or other healthcare professional is anything other than a positive, guiding hand, then you owe it to yourself to find another one. Medical professionals who understand the importance of emotional support for their patients do exist — it is your job to connect with the one that is right for you!" via The Truth About Cancer
"I Have Cancer": 3 Steps to Take After a Cancer Diagnosis
thetruthaboutcancer.com
Being told you have cancer is one of the most stressful experiences a person can go through. Discover practical actions that can help you heal.The non chemothetapy combination of #ibrutinib plus obinutuzumab for the frontline treatment of patients with #CLL is discussed. Recently approved in the USA as a treatment option, it's the first non #chemotherapy combination that has shown promise in all subgroups of CLL "the results of the study were outstanding, with impressive progression-free survival and a nearly 100% response rate" | via OncLive
ow.ly/HWUI30nCLjH
Dr. Kambhampati on Frontline Ibrutinib Plus Obinutuzumab in CLL
onclive.com
Suman Kambhampati, MD, co-medical director, Blood Cancer Program, Sarah Cannon Research Institute, discusses the combination of frontline ibrutinib plus obinutuzumab for the treatment of patients with chronic lymphocytic leukemia.